5 Signs That Your Ongoing Back Pain Could Actually Be Axial Spondyloarthritis
AxSpA can bring on plantar fasciitis, which is when inflammation in the heel causes the sole of your foot to hurt. You may ...
rheumatologyadvisor5d
Alcohol Consumption in Axial Spondyloarthritis Linked to Lower Pain
Alcohol consumption was associated with lower levels of axSpA disease activity and spinal pain, but may be linked to ...
MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab
New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent ...
Acelyrin (NASDAQ:SLRN) Price Target Lowered to $6.00 at HC Wainwright
Acelyrin (NASDAQ:SLRN – Free Report) had its price target reduced by HC Wainwright from $8.00 to $6.00 in a research note released on Tuesday,Benzinga reports. They currently have a neutral rating on ...
Medscape6d
TNF Inhibitors Ward Off Fracture in Axial Spondyloarthritis
TNF inhibitors offered greater protection against fractures than NSAIDs in patients with axial spondyloarthritis (axSpA).
emjreviews.com7d
TNF Inhibitors Lower Fracture Risk in Axial Spondylarthritis
Study finds TNF inhibitors lower hip and spine fracture risk in axial spondyloarthritis, addressing inflammation-related ...
thecardiologyadvisor.com8d
NSAID Use May Not Increase Hypertension Risk in Spondyloarthritis
High-dose nonsteroidal anti-inflammatory drug use among patients with axial spondyloarthritis (axSpA) may not increase the risk of developing hypertension, according to study results presented at the ...
Too Old to Operate8d
Impact of Disease Modifying Therapies on Fracture Incidence in Patients With axSpA
The following is a summary of “Association of Therapies for Axial Spondyloarthritis on the Risk of Hip and Spine Fractures,” published in the December 2024 issue of Rheumatology by Driscoll et al.
Promising Phase 1/2 Results for ACELYRIN’s Lonigutamab Support Buy Rating
Derek Archila, an analyst from Wells Fargo, maintained the Buy rating on ACELYRIN, INC. (SLRN – Research Report). The associated price target ...
ACELYRIN, INC.’s Lonigutamab Program: Balancing Innovation and Uncertainty with a Hold Rating
Analyst Emily Bodnar from H.C. Wainwright reiterated a Hold rating on ACELYRIN, INC. (SLRN – Research Report) and decreased the price target to ...
The Armenian Reporter1d
Acelyrin (NASDAQ:SLRN) Price Target Cut to $6.00 by Analysts at HC Wainwright
Acelyrin (NASDAQ:SLRN – Get Free Report) had its target price lowered by analysts at HC Wainwright from $8.00 to $6.00 in a ...